Healthcare services provider AdaptHealth Corp. (NASDAQ: AHCO) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 7.5% year on year to $740.3 million. The company’s full-year revenue guidance of $2.87 billion at the midpoint came in 17.7% below analysts’ estimates. Its GAAP loss of $0.99 per share was significantly below analysts’ consensus estimates.
Is now the time to buy AdaptHealth? Find out by accessing our full research report, it’s free.
AdaptHealth (AHCO) Q2 CY2026 Highlights:
- Revenue: $740.3 million vs analyst estimates of $847.2 million (7.5% year-on-year decline, 12.6% miss)
- EPS (GAAP): -$0.99 vs analyst estimates of $0.15 (significant miss)
- Adjusted EBITDA: $132 million vs analyst estimates of $160.3 million (17.8% margin, 17.7% miss)
- The company dropped its revenue guidance for the full year to $2.87 billion at the midpoint from $3.49 billion, a 17.6% decrease
- EBITDA guidance for the full year is $505 million at the midpoint, below analyst estimates of $697.2 million
- Operating Margin: -18.6%, down from 9.9% in the same quarter last year
- Free Cash Flow was -$20.94 million, down from $73.33 million in the same quarter last year
- Market Capitalization: $1.44 billion
Company Overview
With a network of approximately 680 locations serving patients across all 50 states, AdaptHealth (NASDAQ: AHCO) provides home medical equipment, supplies, and related services to patients with chronic conditions like sleep apnea, diabetes, and respiratory disorders.
Revenue Growth
A company’s long-term sales performance can indicate its overall quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Thankfully, AdaptHealth’s 13.1% annualized revenue growth over the last five years was solid. Its growth beat the average healthcare company and shows its offerings resonate with customers.
Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. AdaptHealth’s recent performance shows its demand has slowed as its revenue was flat over the last two years. 
This quarter, AdaptHealth missed Wall Street’s estimates and reported a rather uninspiring 7.5% year-on-year revenue decline, generating $740.3 million of revenue.
Looking ahead, sell-side analysts expect revenue to grow 12.1% over the next 12 months, an improvement versus the last two years. This projection is healthy and suggests its newer products and services will catalyze better top-line performance.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
Adjusted Operating Margin
Adjusted operating margin is a key measure of profitability. Think of it as net income (the bottom line) excluding the impact of non-recurring expenses, taxes, and interest on debt - metrics less connected to business fundamentals.
AdaptHealth was profitable over the last five years but held back by its large cost base. Its average adjusted operating margin of 7.2% was weak for a healthcare business.
Looking at the trend in its profitability, AdaptHealth’s adjusted operating margin decreased by 10.2 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 9.4 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn’t pass those costs onto its customers.
In Q2, AdaptHealth generated an adjusted operating margin profit margin of negative 18.6%, down 26.5 percentage points year on year. This contraction shows it was less efficient because its expenses increased relative to its revenue.
Earnings Per Share
Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions.
AdaptHealth’s earnings losses deepened over the last five years as its EPS dropped 1.5% annually. We tend to steer our readers away from companies with falling EPS, where diminishing earnings could imply changing secular trends and preferences. If the tide turns unexpectedly, AdaptHealth’s low margin of safety could leave its stock price susceptible to large downswings.
In Q2, AdaptHealth reported EPS of negative $0.99, down from $0.11 in the same quarter last year. This print missed analysts’ estimates. Over the next 12 months, Wall Street is optimistic. Analysts forecast AdaptHealth’s full-year EPS will flip from negative $1.69 to positive $0.96.
Key Takeaways from AdaptHealth’s Q2 Results
We struggled to find many positives in these results. Its full-year revenue guidance missed and its full-year EBITDA guidance fell short of Wall Street’s estimates. Overall, this was a softer quarter. The stock traded down 25.7% to $8.05 immediately after reporting.
AdaptHealth’s latest earnings report disappointed. One quarter doesn’t define a company’s quality, so let’s explore whether the stock is a buy at the current price. What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here (it’s free).
